Full metadata record

DC Field Value Language
dc.contributor.authorCho, Jung-Kyo-
dc.contributor.authorHong, Ki-Yun-
dc.contributor.authorPark, Jung Won-
dc.contributor.authorYang, Han-Kwang-
dc.contributor.authorSong, Soo-Chang-
dc.date.accessioned2024-01-20T17:04:03Z-
dc.date.available2024-01-20T17:04:03Z-
dc.date.created2021-09-02-
dc.date.issued2011-05-
dc.identifier.issn1061-186X-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/130422-
dc.description.abstract2-Methoxyestradiol (2-ME) has been reported to have antiangiogenic and antitumor activity. Its biomedical application is limited due to its poor water solubility resulting in its low bioavailability. Poly(organophosphazenes) containing L-isoleucine ethyl ester, ethyl-2-(O-glycyl)lactate, and alpha alpha-amino-omega omega-methoxy-poly(ethylene glycol) 550 were synthesized having M(W) of 35-38 kDa and polydispersity index of 2.38-2.73. Using a viscometer, the thermosensitivity useful for locally injectable drug delivery was verified. The aqueous polymer solution showed a sol state at a low temperature and transformed to a gel state at body temperature. The polymer solution (10 wt%) enhanced the solubility of 2-ME by about 10<SU4</SU times compared to that of phosphate buffered saline. 2-ME was released from the hydrogel mainly by diffusion, hydrophobic interaction, and surface erosion of the matrix. This release profile could be confirmed through an in vitro release test as a function of polymers and the concentration of 2-ME in hydrogels. By monitoring tumor volume and CD31 immunohistochemical staining in mouse orthotopic breast tumor (MDA-MB-231) model, it was found that the hydrogel containing a relatively low concentration (15 mg/kg) of 2-ME showed the improved antitumor and antiangiogenic activity relative to the original formulation. This research suggests that the developed formulation of poly(organophosphazenes) may have injectable carrier potentials for 2-ME and other lipophilic drugs.-
dc.languageEnglish-
dc.publisherINFORMA HEALTHCARE-
dc.subjectENDOGENOUS ESTROGEN METABOLITE-
dc.subjectDRUG-DELIVERY-
dc.subjectIN-VITRO-
dc.subjectCONTROLLED-RELEASE-
dc.subjectGENE DELIVERY-
dc.subjectTUMOR-GROWTH-
dc.subjectCELLS-
dc.subjectANGIOGENESIS-
dc.subjectPROTEIN-
dc.subjectPOLYPHOSPHAZENES-
dc.titleInjectable delivery system of 2-methoxyestradiol for breast cancer therapy using biodegradable thermosensitive poly(organophosphazene) hydrogel-
dc.typeArticle-
dc.identifier.doi10.3109/1061186X.2010.499461-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF DRUG TARGETING, v.19, no.4, pp.270 - 280-
dc.citation.titleJOURNAL OF DRUG TARGETING-
dc.citation.volume19-
dc.citation.number4-
dc.citation.startPage270-
dc.citation.endPage280-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000288670900004-
dc.identifier.scopusid2-s2.0-79953005259-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusENDOGENOUS ESTROGEN METABOLITE-
dc.subject.keywordPlusDRUG-DELIVERY-
dc.subject.keywordPlusIN-VITRO-
dc.subject.keywordPlusCONTROLLED-RELEASE-
dc.subject.keywordPlusGENE DELIVERY-
dc.subject.keywordPlusTUMOR-GROWTH-
dc.subject.keywordPlusCELLS-
dc.subject.keywordPlusANGIOGENESIS-
dc.subject.keywordPlusPROTEIN-
dc.subject.keywordPlusPOLYPHOSPHAZENES-
dc.subject.keywordAuthorInjectable-
dc.subject.keywordAuthorhydrogel-
dc.subject.keywordAuthorpoly(organophosphazene)-
dc.subject.keywordAuthor2-methoxyestradiol-
dc.subject.keywordAuthorthermosensitive-
dc.subject.keywordAuthorbiodegradable-
dc.subject.keywordAuthorbreast cancer-
Appears in Collections:
KIST Article > 2011
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE